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Genetic	studies	of	birth	weight	give	biological	insights	into	links	with	adult	
disease		
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Birth	weight	(BW)	is	influenced	by	both	foetal	and	maternal	factors	and	in	observational	studies	is	1	
reproducibly	associated	with	future	risk	of	adult	metabolic	diseases	including	type	2	diabetes	2	
(T2D)	and	cardiovascular	disease1.	These	lifecourse	associations	have	often	been	attributed	to	the	3	
impact	of	an	adverse	early	life	environment.	We	performed	a	multi-ancestry	genome-wide	4	
association	study	(GWAS)	meta-analysis	of	BW	in	153,781	individuals,	identifying	60	loci	where	5	
foetal	genotype	was	associated	with	BW	(P<5x10-8).	Overall,	~15%	of	variance	in	BW	could	be	6	
captured	by	assays	of	foetal	genetic	variation.	Using	genetic	association	alone,	we	found	a	strong	7	
inverse	genetic	correlation	between	BW	and	systolic	blood	pressure	(rg=-0.22,	P=5.5x10-13),	T2D	8	
(rg=-0.27,	P=1.1x10-6)	and	coronary	artery	disease	(rg=-0.30,	P=6.5x10-9)	and,	in	large	cohort	data	9	
sets,	that	genetic	factors	were	the	major	contributor	to	the	negative	covariance	between	BW	and	10	
future	cardiometabolic	risk.	Pathway	analyses	indicated	that	the	protein	products	of	genes	within	11	
BW-associated	regions	were	enriched	for	diverse	processes	including	insulin	signalling,	glucose	12	
homeostasis,	glycogen	biosynthesis	and	chromatin	remodelling.	There	was	also	enrichment	of	13	
associations	with	BW	in	known	imprinted	regions	(P=1.9x10-4).	We	have	demonstrated	that	14	
lifecourse	associations	between	early	growth	phenotypes	and	adult	cardiometabolic	disease	are	in	15	
part	the	result	of	shared	genetic	effects	and	have	highlighted	some	of	the	pathways	through	which	16	
these	causal	genetic	effects	are	mediated.			17	
	18	
We	combined	GWAS	data	for	BW	in	153,781	individuals	representing	multiple	ancestries	from	37	19	
studies	across	three	components	(Extended	Data	1,	Supplementary	Table	1):	(i)	75,891	individuals	20	
of	European	ancestry	from	30	studies;	(ii)	67,786	individuals	of	European	ancestry	from	the	UK	21	
Biobank;	and	(iii)	10,104	individuals	of	diverse	ancestries	(African	American,	Chinese,	Filipino,	22	
Surinamese,	Turkish	and	Moroccan)	from	six	studies.	Within	each	study,	BW	was	z-score	23	
transformed	separately	in	males	and	females	after	excluding	non-singletons	and	premature	births	24	
and	adjusting	for	gestational	age	where	available.	Genotypes	were	imputed	using	reference	panels	25	
from	the	1000	Genomes	(1000G)2	or	combined	1000G	and	UK10K	Project3	(Supplementary	Table	2).	26	
We	performed	quality	control	assessments	to	confirm	that	the	distribution	of	BW	was	consistent	27	
across	studies,	irrespective	of	the	data	collection	protocol,	and	confirmed	that	self-reported	BW	in	28	
UK	Biobank	showed	genetic	and	phenotypic	associations	consistent	with	those	seen	for	measured	29	
BW	in	other	studies4	(Methods).		30	
		31	
We	identified	60	loci	(59	autosomal)	associated	with	BW	at	genome-wide	significance	(P<5x10-8)	in	32	
either	the	European	ancestry	or	trans-ancestry	meta-analyses	(Figure	1a,	Extended	Data	2,	33	
Supplementary	Data;	Methods).	At	lead	SNPs,	we	observed	no	heterogeneity	in	allelic	effects	34	
between	the	three	study	components	(Cochran’s	Q	statistic	P>0.00083)	(Supplementary	Table	3).	35	
Fifty-three	of	these	loci	were	novel	in	that	the	lead	SNP	mapped	>2Mb	away	from,	and	was	36	
statistically	independent	(EUR	r2<0.05)	of,	the	seven	previously-reported	BW	signals5,	all	of	which	37	
were	confirmed	in	this	larger	analysis	(Supplementary	Table	4).	Approximate	conditional	analysis	in	38	
the	European	ancestry	data	indicated	that	three	of	these	novel	loci	(near	ZBTB7B,	HMGA1	and	39	
PTCH1)	harboured	multiple	distinct	association	signals	attaining	genome-wide	significance	40	
(Methods;	Supplementary	Table	5,	Extended	Data	3).		41	
	42	
The	lead	variants	for	most	signals	mapped	to	non-coding	sequence,	and	at	only	two	loci,	ADRB1	43	
(rs7076938;	r2=0.99	with	ADRB1	G389R)	and	NRIP1	(rs2229742,	R448G)	did	the	association	data	44	
point	to	likely	causal	non-synonymous	coding	variants	(Supplementary	Table	6;	Methods).	Lead	45	
SNPs	for	all	but	two	loci	(those	mapping	near	YKT6-GCK	and	SUZ12P1-CRLF3)	were	common	(minor	46	
allele	frequency	(MAF)≥5%)	with	individually	modest	effects	on	BW	(β=0.020-0.053	per	allele,	47	
equivalent	to	10	to	26g).	This	was	despite	much	improved	coverage	of	low-frequency	variants	in	this	48	
study	(compared	to	previous	HapMap	2	imputed	meta-analyses5)	reflecting	imputation	from	larger,	49	
and	more	complete,	reference	panels	(Extended	Data	4).	Indeed,	all	but	five	of	the	common	variant	50	
association	signals	were	tagged	by	variants	(EUR	r2>0.6)	in	the	HapMap	2	reference	panel	51	
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(Supplementary	Tables	4	and	5),	indicating	that	most	of	the	novel	discovery	in	the	present	study	52	
was	driven	by	increased	sample	size5.	Fine-mapping	analysis	yielded	14	regions	within	which	fewer	53	
than	ten	variants	contributed	to	the	locus-specific	“credible	set”	accounting	for	>99%	of	the	54	
posterior	probability	of	association	(Methods;	Supplementary	Table	7).	Collectively,	these	credible	55	
set	variants	showed	enrichment	for	overlap	with	DNaseI	hypersensitivity	sites,	particularly	those	56	
generated	by	ENCODE,	from	foetal	(4.2-fold,	95%	CI	[1.8-10.7])	and	neonatal	tissues	(4.9	[1.8-11.0])	57	
(Supplementary	Table	8;	Methods).	The	greatest	refinement	was	at	YKT6-GCK,	where	the	credible	58	
set	included	only	the	low	frequency	variant	rs138715366,	which	maps	intronic	to	YKT6.		59	
	60	
In	combination,	the	62	distinct	genome-wide	significant	signals	at	the	59	autosomal	loci,	explained	61	
2.0%	(standard	error	(SE)	1.1%)	of	variance	in	BW	(Supplementary	Table	9;	Methods),	similar	in	62	
magnitude	to	that	attributable	to	sex	or	maternal	body	mass	index	(BMI)5.	However,	the	variance	in	63	
BW	captured	collectively	by	all	autosomal	genotyped	variants	on	the	array	was	considerably	larger,	64	
estimated	at	15.1%	(SE=0.9)	in	UK	Biobank	(Methods).	These	figures	are	consistent	with	a	long	tail	of	65	
genetic	variants	of	smaller	effects	contributing	to	variation	in	BW.	66	
	67	
Associations	between	foetal	genotype	and	BW	could	result	from	indirect	effects	of	the	maternal	68	
genotype	(r	with	foetal	genotype	≈	0.5)	influencing	BW	via	the	intrauterine	environment.	However,	69	
two	lines	of	evidence	indicated	that	variation	in	the	foetal	genome	was	the	predominant	driver	of	70	
the	BW	associations.	First,	an	analysis	of	the	global	contribution	of	maternal	vs.	foetal	genetic	71	
variation,	using	a	maternal-GCTA	model6	in	4,382	mother-child	pairs,	estimated	that	the	child’s	72	
genotype	(σC2=0.24,	SE=0.11)	makes	a	larger	contribution	to	BW	variance	than	either	the	mother’s	73	
genotype	(σM2=0.04,	SE=0.10),	or	the	covariance	between	the	two	(σCM=0.04,	SE=0.08).	Second,	74	
when	we	compared,	at	each	of	the	60	loci,	the	point	estimates	of	the	BW	effect	size	dependent	on	75	
maternal	genotype	(as	measured	in	up	to	68,254	women7)	with	those	dependent	on	foetal	genotype	76	
(using	European	ancestry	data	from	143,677	individuals	in	the	present	study),	foetal	variation	had	77	
greater	impact	than	maternal	at	93%	of	loci	(55/60;	binomial	P=1x10-11)	(Supplementary	Table	10,	78	
Extended	Data	5	and	6;	Methods).	Notably,	the	association	at	MTNR1B,	one	of	the	five	loci	at	which	79	
the	maternal	effect	size	exceeded	the	foetal	(maternal:	β=0.048,	P=5.1x10-15;	foetal:	β=0.023,	80	
P=2.9x10-8),	is	consistent	with	prior	evidence	pointing	towards	a	maternal	effect:	MTNR1B	variation	81	
is	associated	with	hyperglycaemia	and	impaired	glucose	tolerance8,9	and	these	in	turn	have	been	82	
shown	to	be	causally	related	to	offspring	BW10,11.	Power	to	disentangle	maternal	and	foetal	83	
contributions	using	analyses	of	foetal	genotype	conditional	on	maternal	genotype	was	constrained	84	
by	the	limited	sample	size	available	(n=12,909	mother-child	pairs)	(Supplementary	Table	11).		85	
	86	
These	analyses	collectively	provide	compelling	evidence	that	foetal	genotype	has	a	substantial	87	
impact	on	early	growth,	as	measured	by	BW.	We	sought	to	use	these	genetic	associations	to	88	
understand	the	causal	relationships	between	the	observed	BW-disease	associations	and	to	89	
characterise	the	underlying	processes	responsible.				90	
	 	91	
To	quantify	the	shared	genetic	contribution	to	BW	and	other	health-related	traits,	we	estimated	92	
their	genetic	correlations	using	LD	Score	regression12	(Methods).	BW	(in	European	ancestry	samples)	93	
showed	strong	positive	genetic	correlations	with	anthropometric	and	obesity-related	traits	including	94	
birth	length	(rg=0.81,	P=2.0x10-44),	and	in	adults,	height	(rg=0.41,	P=4.8x10-52),	waist	circumference	95	
(rg=0.18,	P=3.9x10-10)	and	BMI	(rg=0.11,	P=7.3x10-6).	In	contrast,	BW	showed	inverse	genetic	96	
correlations	with	indicators	of	adverse	metabolic	and	cardiovascular	health	including	coronary	artery	97	
disease	(CAD	rg=-0.30,	P=6.5x10-9),	systolic	blood	pressure	(SBP	rg=-0.22,	P=5.5x10-13)	and	T2D	(rg=-98	
0.27,	P=1.1x10-6)	(Figure	2,	Supplementary	Table	12).	These	correlations	between	BW	and	adult	99	
cardiometabolic	phenotypes	are	of	similar	magnitude,	although	directionally-opposite,	to	the	100	
reported	genetic	correlations	between	adult	BMI	and	those	same	cardiometabolic	outcomes12.	101	
These	findings	support	observational	associations	between	paternal	T2D	and	lower	BW4,	and	102	
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establish	more	generally	that	the	observed	lifecourse	associations	between	early	growth	and	adult	103	
disease,	at	least	in	part,	reflect	the	impact	of	shared	genetic	variants	that	influence	both	directly.	In	104	
an	effort	to	estimate	the	extent	of	genetic	contribution	to	these	lifecourse	associations,	we	first	105	
focused	on	data	from	UK	Biobank	(n=57,715).	For	many	of	the	traits	for	which	data	were	available,	106	
genetic	variation	significantly	contributed	to	the	lifecourse	relationship	between	BW	and	adult	107	
phenotypes,	and	in	some	cases	appeared	to	be	the	major	source	of	covariance	between	the	traits.	108	
For	example,	we	estimated	that	85%	(95%	CI=70%-99%)	of	the	negative	covariance	between	BW	and	109	
SBP	was	explained	by	shared	genetic	associations	captured	by	directly	genotyped	SNPs	110	
(Supplementary	Table	13).	For	continuous	cardiometabolic	measures,	including	lipids	and	fasting	111	
glycaemia,	for	which	measures	are	not	currently	available	in	UK	Biobank,	we	turned	to	the	Northern	112	
Finland	Birth	Cohort	(n=5,009),	and	obtained	similar	results	(Supplementary	Table	13).	However,	113	
these	estimates	are	limited,	not	only	by	wide	confidence	intervals,	but	also	by	the	assumption	of	a	114	
linear	relationship	between	BW	and	each	of	the	phenotypes	and	inability	to	explicitly	model	115	
maternal	genotypic	effects.	In	other	words,	the	negative	genetic	correlations	between	BW	and	116	
cardiometabolic	traits	may	not	exclusively	reflect	genetic	effects	mediated	directly	through	the	117	
offspring,	but	also	effects	mediated	by	maternal	genotype	acting	indirectly	via	perturbation	of	the	in	118	
utero	environment.	Nevertheless,	these	estimates	indicate	that	a	substantial	proportion	of	the	119	
variance	in	cardiometabolic	risk	that	covaries	with	BW	can	be	attributed	to	the	effects	of	common	120	
genetic	variation.	121	
	122	
To	elucidate	the	biological	pathways	and	processes	underlying	regulation	of	foetal	growth,	we	first	123	
performed	gene	set	enrichment	analysis	of	our	BW	GWAS	analysis	using	MAGENTA13	(Methods).	124	
Twelve	pathways	reached	study-wide	significance	(FDR<0.05),	including	pathways	involved	in	125	
metabolism	(insulin	signalling,	glycogen	biosynthesis,	cholesterol	biosynthesis),	growth	(IGF-126	
signalling,	growth	hormone	pathway)	and	development	(chromatin	remodelling)	(Extended	Data	127	
7a).	Similar	pathways	were	detected	in	a	complementary	analysis	where	we	interrogated	empirical	128	
protein-protein	interaction	(PPI)	data	(collated	within	Inweb14)	identifying	13	PPI	network	modules	129	
with	marked	(z-score>5)	enrichment	for	BW-association	scores	(Extended	Data	7b	and	8a,b;	130	
Methods).	The	proteins	within	these	modules	were	themselves	enriched	for	diverse	processes	131	
related	to	metabolism,	growth	and	development	(Extended	Data	8a,b).			132	
	133	
We	also	observed	enrichment	of	BW	association	signals	across	the	set	of	77	imprinted	genes	defined	134	
by	the	Genotype-Tissue	Expression	(GTEx)	project15	(P=1.9	x	10-4;	Extended	Data	7a,	Supplementary	135	
Table	14).	Such	enrichment	is	consistent	with	the	“parental	conflict”	hypothesis	regarding	the	136	
allocation	of	maternal	resources	to	the	foetus16.	Although	the	role	of	imprinted	genes	in	foetal	137	
growth	is	described	in	animal	models	and	rare	human	disorders17,	our	result	is	the	first	large-scale,	138	
systematic	demonstration	of	their	contribution	to	normal	variation	in	BW.	Of	the	60	genome-wide	139	
significant	loci,	two	(INS-IGF2,	RB1)	fall	within	(or	near)	imprinted	regions	(Figure	1b),	with	a	140	
noteworthy	third	signal	at	DLK1	(previously	foetal	antigen-1;	P=5.6x10-8).	Parent-of-origin	specific	141	
analyses	to	further	investigate	these	individual	loci	(comparing	heterozygote	vs.	homozygote	BW	142	
variance	in	57,715	unrelated	individuals	and	testing	BW	associations	with	paternal	vs.	maternal	143	
alleles	in	4,908	mother-child	pairs;	see	Methods)	proved,	despite	these	sample	sizes,	to	be	144	
underpowered	(Extended	Data	9,	Supplementary	Tables	15	and	16).		145	
	146	
Many	of	the	genome-wide	signals	for	BW	detected	here	are	also	established	genome-wide	147	
association	signals	for	a	wide	variety	of	cardiometabolic	traits	(Figure	3).	These	include	the	BW	148	
signals	near	CDKAL1,	ADCY5,	HHEX/IDE	and	ANK1	(also	genome-wide	significant	for	T2D),	NT5C2	and	149	
ADRB1	(BP/CAD/BMI).	We	used	two	approaches	to	understand	whether	this	pattern	of	adult	trait	150	
association	represented	a	generic	property	of	BW-associated	loci,	or	reflected	heterogeneous	151	
mechanisms	linking	BW	to	adult	disease.		152	
	153	
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First,	we	applied	unsupervised	hierarchical	clustering	(Methods)	to	the	non-BW	trait	association	154	
statistics	for	the	60	significant	BW	loci.	The	resultant	heatmap	indicates	the	heterogeneity	of	155	
between-locus	effect-size	across	the	range	of	adult	traits	(Figure	3,	Supplementary	Table	17).	For	156	
example,	it	shows	that	the	associations	between	BW-raising	alleles	and	increased	adult	height	157	
concentrated	amongst	a	subset	of	loci	including	HHIP	and	GNA12,	and	highlights	particularly	strong	158	
associations	with	lipid	traits	for	variants	at	the	TRIB1	and	MAFB	loci.			159	
	160	
Second,	we	constructed	trait-specific	“point-of-contact”	(PoC)	PPI	networks	from	proteins	161	
represented	in	both	the	global	BW	PPI	network	and	equivalent	PPI	networks	generated	for	each	of	162	
the	adult	traits	(Methods;	Extended	Data	8c-e).	We	reasoned	that	these	PoC	PPI	networks	would	be	163	
enriched	for	the	specific	proteins	mediating	the	observed	links	between	BW	and	adult	traits.	To	164	
highlight	processes	implicated	in	specific	BW-trait	associations,	we	overlaid	these	PoC	PPI	with	the	165	
50	pathways	over-represented	in	the	global	BW	PPI	network.	These	analyses	revealed,	for	example,	166	
that	proteins	in	the	Wnt	canonical	signalling	pathway	were	only	detected	in	the	PoC	PPI	network	for	167	
BP	traits.	We	can	use	these	PPI	overlaps	to	highlight	the	specific	transcripts	within	BW	GWAS	loci	168	
that	are	likely	to	mediate	the	mechanistic	links.	For	example,	the	overlap	between	the	Wnt	signalling	169	
pathway	and	the	PoC	PPI	network	for	the	intersection	of	BW	and	BP-related	traits	implicates	FZD9	as	170	
the	likely	effector	gene	at	the	MLXIPL	BW	locus	(Extended	Data	8d,	Supplementary	Table	6).		171	
	172	
We	focused	our	more	detailed	investigation	of	the	mechanistic	links	between	early	growth	and	adult	173	
traits	on	two	phenotypic	areas:	arterial	BP	and	T2D/glycaemia.	174	
	175	
Across	both	the	overall	GWAS	and	specifically	among	the	60	significant	BW	loci,	most	BW-raising	176	
alleles	were	associated	with	reduced	BP	(Figures	2,	3):	the	strongest	inverse	associations	were	seen	177	
for	the	loci	near	NT5C2,	FES,	NRIP1,	EBF1	and	PTH1R.	However,	we	also	observed	locus-specific	178	
heterogeneity	in	the	genetic	relationships	between	BP	and	BW:	the	SBP-raising	allele	at	ADRB118	is	179	
associated	with	higher,	rather	than	lower,	BW	(Extended	Data	10a).	When	we	considered	the	180	
reciprocal	relationship,	i.e.	the	effects	on	BW	of	BP-raising	alleles	at	30	reported	loci	for	SBP18,19,	181	
there	was	an	excess	of	associations	(5/30	with	lower	BW	at	P<0.05;	P=0.0026;	Extended	Data	10a).	182	
To	dissect	maternal	and	foetal	genotype	effects	at	these	loci,	we	tested	the	impact	on	BW	of	a	risk	183	
score	generated	from	30	SBP	SNPs,	restricted	to	the	untransmitted	maternal	haplotype	score20	in	a	184	
set	of	5,201	mother-child	pairs.	Analysis	of	these	loci	indicated	that	maternal	genotype	effects	on	185	
intrauterine	environment	are	likely	to	contribute	to	the	inverse	genetic	correlation	between	SBP	and	186	
BW	(Methods;	Supplementary	Table	18),	and	was	consistent	with	the	results	of	a	wider	study	of	187	
>30,000	women	which	demonstrated	associations	between	a	maternal	genetic	score	for	SBP	188	
(conditional	on	foetal	genotype)	and	lower	offspring	BW10.				189	
	190	
The	BP-raising	allele	with	the	largest	BW-lowering	effect	maps	to	the	NT5C2	locus	(index	variant	for	191	
BW,	rs74233809,	r2=0.98	with	index	variant	for	BP,	rs1119154819)	and	is	also	associated	with	lower	192	
adult	BMI	(r2=0.99	with	rs1119156021).	The	BW-lowering	allele	at	rs74233809	is	a	proxy	for	a	193	
recently-described	functional	variant	in	the	nearby	CYP17A1	gene	(r2=0.92	with	rs138009835)22.	The	194	
CYP17A1	gene	encodes	the	cytochrome	P450c17α	enzyme,	CYP1723,	which	catalyses	key	steps	in	195	
steroidogenesis	that	determine	the	balance	between	mineralocorticoid,	glucocorticoid	and	196	
androgen	synthesis.	This	variant	is	known	to	alter	transcriptional	efficiency	in	vitro	and	is	associated	197	
with	higher	urinary	tetrahydroaldosterone	excretion22.	CYP17A1	is	expressed	in	foetal	adrenal	glands	198	
and	testes	from	early	gestation24	as	well	as	in	the	placenta25.	These	data	implicate	variation	in	199	
CYP17A1	expression	as	a	contributor	to	the	observational	association	between	low	BW	and	adult	200	
hypertension26.		201	
	202	
When	we	examined	45	loci	associated	with	CAD27,	the	inverse	genetic	correlation	between	CAD	and	203	
BW	was	concentrated	amongst	the	five	CAD	loci	with	primary	BP	associations.	This	suggests	that	204	
	 10	
genetic	determinants	of	BP	play	a	leading	role	in	mediating	the	lifecourse	associations	between	BW	205	
and	CAD	(Extended	Data	10b,e).		206	
	207	
The	LD	score	regression	analyses	demonstrated	overall	inverse	genetic	correlation	between	lower	208	
BW	and	elevated	risk	of	T2D	(Figure	2).	However,	the	locus	specific	heatmap	indicates	a	209	
heterogeneous	pattern	across	individual	loci	(Figure	3).	To	explore	this	further,	we	tested	the	84	210	
reported	T2D	loci28	for	association	with	BW.	Some	T2D	risk	alleles	(such	as	at	ADCY5,	CDKAL1	and	211	
HHEX-IDE)	were	strongly	associated	with	lower	BW,	whilst	others	(e.g.	ANK1	and	MTNR1B)	were	212	
associated	with	higher	(Extended	Data	10c).	This	was	in	contrast	with	the	BW	effects	of	422	known	213	
height	loci29	(Extended	Data	10d),	which	showed	a	strong	positive	correlation	consistent	with	the	214	
overall	genetic	correlation	between	height	and	BW,	indicating	that	the	growth	effects	of	many	215	
height	loci	start	prenatally	and	persist	into	adulthood.		216	
	217	
The	contrasting	associations	of	T2D	risk-alleles	with	both	higher	and	lower	BW	are	likely	to	reflect	218	
the	differential	impacts	across	loci	of	variation	in	the	maternal	and	foetal	genomes.	Observational	219	
data	link	paternal	diabetes	with	lower	offspring	BW4	indicating	that	the	inheritance	of	T2D	risk	220	
alleles	by	the	foetus	tends,	in	line	with	the	LD	score	regression	analysis,	to	reduce	growth.	These	221	
relationships	are	consistent	with	the	precepts	of	the	“foetal	insulin	hypothesis”30	and	reflect	the	222	
potential	for	reduced	insulin	secretion	and/or	signalling	to	lead	to	both	reduced	foetal	growth	and,	223	
many	decades	later,	enhanced	predisposition	to	T2D.	In	line	with	this,	the	paternal	transmitted	224	
haplotype	score	generated	from	the	84	T2D	risk	variants	was	associated	with	lower	BW	(P=0.045)	in	225	
5,201	mother-child	pairs	(Methods;	Supplementary	Table	18).	In	contrast,	maternal	diabetes	is	226	
observationally	associated	with	higher	offspring	BW4,	reflecting	the	impact	of	maternal	227	
hyperglycaemia	to	stimulate	foetal	insulin	secretion.	The	contribution	of	genotype-dependent	228	
maternal	hyperglycaemia	to	BW	is	in	line	with	the	observation	that	some	T2D	risk	alleles	(most	229	
notably	at	MTNR1B)	are	associated	with	higher	BW7,	and	with	evidence,	from	a	recent	study,	that	a	230	
maternal	genetic	score	for	T2D	(conditional	on	foetal	genotype)	was	associated	with	higher	offspring	231	
BW10.	Thus,	both	maternal	and	foetal	genetic	effects	connect	BW	to	later	T2D	risk,	albeit	acting	in	232	
opposing	directions.	When	we	categorised	T2D	loci	using	a	classification	of	physiological	function	233	
derived	from	their	effects	on	related	glycaemic	and	anthropometric	traits31,	we	found	that	T2D-risk	234	
alleles	associated	with	lower	BW	were	those	typically	characterised	by	reduced	insulin	processing	235	
and	secretion	without	detectable	changes	in	fasting	glucose	(the	“Beta	Cell”	cluster	in	Extended	236	
Data	10f).		237	
	238	
The	YTK6	signal	at	rs138715366	is	notable,	not	only	because	the	genetic	data	indicates	that	a	single	239	
low-frequency	non-coding	variant	is	driving	the	association	signal	(see	above)	but	because	of	the	240	
proximity	of	this	signal	to	GCK.	Rare	coding	variants	in	glucokinase	are	causal	for	a	form	of	241	
monogenic	hyperglycaemia	and	lead	to	large	reductions	in	BW	when	parental	alleles	are	passed	to	242	
their	offspring32.	In	addition,	common	non-coding	variants	nearby	are	implicated	in	T2D-risk	and	243	
fasting	hyperglycaemia33,34.	However,	the	latter	variants	are	conditionally	independent	of	244	
rs138715366	(Supplementary	Table	19)	and	show	no	comparable	association	with	lower	BW.	Either	245	
rs138715366	acts	through	effector	transcripts	other	than	GCK,	or	the	impact	of	the	low-frequency	246	
SNP	near	YKT6	on	GCK	expression	involves	tissue-	and/or	temporal-specific	variation	in	regulatory	247	
impact.	248	
	249	
In	conclusion,	we	have	identified	60	genetic	loci	associated	with	BW	and	used	these	to	gain	insights	250	
into	the	aetiology	of	foetal	growth	and	into	well-established,	but	until	now	poorly	understood,	251	
lifecourse	disease	associations.	The	evidence	that	the	relationship	between	early	growth	and	later	252	
metabolic	disease	has	an	appreciable	genetic	component	contrasts	with,	but	is	not	necessarily 253	
incompatible	with,	the	emphasis	on	adverse	early	environmental	events	highlighted	by	the	Foetal	254	
Origins	Hypothesis1.	As	we	have	shown,	these	genetic	effects	reflect	variation	in	both	the	foetal	and	255	
	 11	
the	maternal	genome:	the	impact	of	the	latter	on	the	offspring’s	predisposition	to	adult	disease	256	
could	be	mediated,	at	least	in	part,	through	perturbation	of	the	antenatal	and	early	life	257	
environment.	Future	mechanistic	and	genetic	studies	should	support	reconciliation	between	these	258	
alternative,	but	complementary,	explanations	for	the	powerful	lifecourse	associations	that	exist	259	
between	events	in	early	life	and	predisposition	to	cardiometabolic	disease	several	decades	later.		260	
	261	
	262	
	263	
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METHODS	358	
	359	
Ethics	statement.	All	human	research	was	approved	by	the	relevant	institutional	review	boards	and	360	
conducted	according	to	the	Declaration	of	Helsinki.	All	participants	provided	written	informed	361	
consent.	Ethical	approval	for	the	study	was	obtained	from	the	ALSPAC	Ethics	and	Law	Committee	362	
and	the	Local	Research	Ethics	Committees.	363	
	364	
Study-level	analyses.	Within	each	study,	BW	was	collected	from	a	variety	of	sources,	including	365	
measurements	at	birth	by	medical	practitioners,	obstetric	records,	medical	registers,	interviews	with	366	
the	mother	and	self-report	as	adults	(Supplementary	Table	1).	BW	was	z-score	transformed,	367	
separately	in	males	and	females.	Individuals	with	extreme	BW	(>5	standard	deviations	(SD)	from	the	368	
sex-specific	study	mean),	monozygotic	or	polyzygotic	siblings,	or	preterm	births	(gestational	age	<37	369	
weeks,	where	this	information	was	available)	were	excluded	from	downstream	association	analyses	370	
(Supplementary	Table	1).	371	
Within	each	study,	stringent	quality	control	of	the	GWAS	genotype	scaffold	was	undertaken,	372	
prior	to	imputation	(Supplementary	Table	2).	Each	scaffold	was	then	pre-phased	and	imputed35,36		373	
up	to	reference	panels	from	the	1000	Genomes	Project	Consortium2	or	1000G	and	UK10K	Project	374	
Consortium3	(Supplementary	Table	2).	Association	of	BW	with	each	variant	passing	established	375	
GWAS	quality	control	filters37	was	tested	in	a	linear	regression	framework,	under	an	additive	model	376	
for	the	allelic	effect,	after	adjustment	for	study-specific	covariates,	including	gestational	age,	where	377	
available	(Supplementary	Table	2).	Where	necessary,	population	structure	was	accounted	for	by	378	
adjustment	for	axes	of	genetic	variation	from	principal	components	analysis38	and	subsequent	379	
genomic	control	correction39,	or	inclusion	of	a	genetic	relationship	matrix	in	a	mixed	model40	380	
(Supplementary	Table	2). We	calculated	the	genomic	control	inflation	factor	(λ)	in	each	study	to	381	
confirm	that	study-level	population	structure	was	accounted	for	prior	to	meta-analysis.	382	
	383	
Preparation,	quality	control	and	genetic	analysis	in	UK	Biobank	samples.	UK	Biobank	phenotype	384	
data	were	available	for	502,655	participants41.	All	participants	in	the	UK	Biobank	were	asked	to	recall	385	
their	BW,	of	which	279,971	did	so	at	either	the	baseline	or	follow-up	assessment	visit.	Of	these,	386	
7,686	participants	reported	being	part	of	multiple	births	and	were	excluded	from	downstream	387	
analyses.	Ancestry	checks,	based	on	self-reported	ancestry,	resulted	in	the	exclusion	of	8,998	388	
additional	participants	reported	not	to	be	white	European.	Of	those	individuals	reporting	BW	at	389	
baseline	and	follow-up	assessments,	393	were	excluded	because	the	two	reported	values	differed	by	390	
more	than	0.5	kg.	For	those	reporting	different	values	(≤0.5	kg)	between	baseline	and	follow-up,	we	391	
took	the	baseline	measure	forward	for	downstream	analyses.	We	then	excluded	36,716	individuals	392	
reporting	values	<2.5	kg	or	>4.5	kg	as	implausible	for	live	term	births	before	1970.	In	total	226,178	393	
participants	had	data	relating	to	BW	that	matched	these	inclusion	criteria.		394	
Genotype	data	from	the	May	2015	release	were	available	for	a	subset	of	152,249	395	
participants	from	UK	Biobank.	In	addition	to	the	quality	control	metrics	performed	centrally	by	UK	396	
Biobank,	we	defined	a	subset	of	“white	European”	ancestry	samples	using	a	K-means	(K=4)	397	
clustering	approach	based	on	the	first	four	genetically	determined	principal	components.	A	398	
maximum	of	67,786	individuals	(40,425	females	and	27,361	males)	with	genotype	and	valid	BW	399	
measures	were	available	for	downstream	analyses.	We	tested	for	association	with	BW,	assuming	an	400	
additive	allelic	effect,	in	a	linear	mixed	model	implemented	in	BOLT-LMM42	to	account	for	cryptic	401	
population	structure	and	relatedness.	Genotyping	array	was	included	as	a	binary	covariate	in	all	402	
models.	Total	chip	heritability	(i.e.	the	variance	explained	by	all	autosomal	polymorphic	genotyped	403	
SNPs	passing	quality	control)	was	calculated	using	Restricted	Maximum	Likelihood	(REML)	404	
implemented	in	BOLT-LMM42.	We	additionally	analysed	the	association	between	BW	and	directly	405	
genotyped	SNPs	on	the	X	chromosome:	for	this	analysis,	we	used	57,715	unrelated	individuals	with	406	
BW	available	and	identified	by	UK	Biobank	as	white	British.	We	excluded	SNPs	with	evidence	of	407	
deviation	from	Hardy-Weinberg	Equilibrium	(P<1x10-6),	MAF<0.01	or	overall	missing	rate	>0.015,	408	
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resulting	in	19,423	SNPs	for	analysis	in	Plink	v1.07	(http://pngu.mgh.harvard.edu/purcell/plink/)43,	409	
with	the	first	five	ancestry	principal	components	as	covariates.		410	
In	both	the	full	UK	Biobank	sample	and	our	refined	sample,	we	observed	that	BW	was	411	
associated	with	sex,	year	of	birth	and	maternal	smoking	(P<0.0015,	all	in	the	expected	directions),	412	
confirming	more	comprehensive	previous	validation	of	self-reported	BW4.	We	additionally	verified	413	
that	BW	associations	with	lead	SNPs	at	seven	established	loci5	based	on	self-report	in	UK	Biobank	414	
were	consistent	with	those	previously	published.	415	
	416	
European	ancestry	meta-analysis.	The	European	ancestry	meta-analysis	consisted	of	two	417	
components:	(i)	75,891	individuals	from	30	GWAS	from	Europe,	USA	and	Australia;	and	(ii)	67,786	418	
individuals	of	white	European	origin	from	UK	Biobank.	In	the	first	component,	we	combined	sex-419	
specific	BW	association	summary	statistics	across	studies	in	a	fixed-effects	meta-analysis,	420	
implemented	in	GWAMA44	and	applied	a	second	round	of	genomic	control39	(λGC=	1.001).	421	
Subsequently,	we	combined	association	summary	statistics	from	this	component	with	UK	Biobank	in	422	
a	European	ancestry	fixed-effects	meta-analysis,	implemented	in	GWAMA44.	Variants	failing	GWAS	423	
quality	control	filters	in	UK	Biobank,	reported	in	less	than	50%	of	the	total	sample	size	in	the	first	424	
component,	or	with	MAF<0.1%,	were	excluded	from	the	European	ancestry	meta-analysis.	We	meta-425	
analysed	the	X-Chromosome	UK	Biobank	results	(19,423	SNPs)	with	corresponding	results	from	the	426	
European	ancestry	meta-analysis	using	fixed	effects	P-value	based	meta-analysis	in	METAL45	(max	427	
N=99,152).		428	
We	were	concerned	that	self-reported	BW	as	adults	in	UK	Biobank	would	not	be	comparable	429	
with	that	obtained	from	more	stringent	collection	methods	used	in	other	European	ancestry	GWAS.	430	
In	addition,	UK	BioBank	lacked	information	on	gestational	age	for	adjustment,	which	could	have	an	431	
impact	on	difference	in	strength	of	association	compared	to	the	results	obtained	from	other	432	
European	ancestry	GWAS.	However,	we	observed	no	evidence	of	heterogeneity	in	BW	allelic	effects	433	
at	lead	SNPs	between	the	two	components	of	European	ancestry	meta-analysis,	using	Cochran’s	Q	434	
statistic46,	implemented	in	GWAMA44,	after	Bonferroni	correction	(P>0.00083)	(Supplementary	435	
Table	3).	We	tested	for	heterogeneity	in	allelic	effects	between	studies	within	the	European	436	
component	using	Cochran’s	Q.	At	loci	demonstrating	evidence	of	heterogeneity,	we	confirmed	that	437	
association	signals	were	not	being	driven	by	outlying	studies by	visual	inspection	of	forest	plots.	We	438	
performed	sensitivity	analyses	to	assess	the	impact	of	covariate	adjustment	(gestational	age	and	439	
population	structure)	on	heterogeneity.		440	
We	were	also	concerned	that	overlap	of	individuals	(duplicated	or	related)	between	the	two	441	
components	of	the	European	ancestry	meta-analysis	might	lead	to	false	positive	association	signals.	442	
We	performed	bivariate	LD	Score	regression12	using	the	two	components	of	the	European	ancestry	443	
meta-analysis	and	observed	a	genetic	covariance	intercept	of	0.0156	(SE	0.0058),	indicating	a	444	
maximum	of	1,119	duplicate	individuals.	Univariate	LD	Score	regression12	of	the	European	ancestry	445	
meta-analysis	estimated	the	intercept	as	1.0426,	which	may	indicate	population	structure	or	446	
relatedness	that	is	not	adequately	accounted	for	in	the	analysis.	To	assess	the	impact	of	this	inflation	447	
on	the	European	ancestry	meta-analysis,	we	expanded	the	standard	errors	of	BW	allelic	effect	size	448	
estimates	and	re-calculated	association	P-values.	On	the	basis	of	this	adjusted	analysis,	the	lead	SNP	449	
only	at	MTNR1B	dropped	below	genome-wide	significance	(rs10830963,	P=5.5x10-8).	450	
	451	
Trans-ancestry	meta-analysis.	The	trans-ancestry	meta-analysis	combined	the	two	European	452	
ancestry	components	with	an	additional	10,104	individuals	from	six	GWAS	from	diverse	ancestry	453	
groups:	African	American,	Chinese,	Filipino,	Surinamese,	Turkish	and	Moroccan.	Within	each	GWAS,	454	
we	first	combined	sex-specific	BW	association	summary	statistics	in	a	fixed-effects	meta-analysis,	455	
implemented	in	GWAMA44	and	applied	a	second	round	of	genomic	control39.	Subsequently,	we	456	
combined	association	summary	statistics	from	the	six	non-European	GWAS	and	the	two	European	457	
ancestry	components	in	a	trans-ancestry	fixed-effects	meta-analysis,	implemented	in	GWAMA44.	458	
Variants	failing	GWAS	quality	control	filters	in	UK	Biobank,	reported	in	less	than	50%	of	the	total	459	
	 16	
sample	size	in	the	first	component,	or	with	MAF	<0.1%,	were	excluded	from	the	trans-ancestry	460	
meta-analysis.	We	tested	for	heterogeneity	in	allelic	effects	between	ancestries	using	Cochran’s	Q46.					461	
	462	
Prioritising	candidate	genes	in	each	BW	locus.	We	combined	a	number	of	approaches	to	prioritise	463	
the	most	likely	candidate	gene(s)	in	each	BW	locus.	Expression	quantitative	trait	loci	(eQTLs)	were	464	
obtained	from	the	Genotype	Tissue	Expression	(GTEx)	Project47,	the	GEUVADIS	Project48	and	eleven	465	
other	studies49-59	using	HaploReg	v460.	We	interrogated	coding	variants	for	each	BW	lead	SNP	and	its	466	
proxies	(EUR	r2>0.8)	using	Ensembl61	and	HaploReg.	Their	likely	functional	consequences	were	467	
predicted	by	SIFT62	and	PolyPhen263.	Biological	candidacy	was	assessed	by	presence	in	significantly	468	
enriched	gene	set	pathways	from	MAGENTA	analyses	(see	below	for	details).	We	extracted	all	genes	469	
within	300	kb	of	all	lead	BW	SNPs	and	searched	for	connectivity	between	any	genes	using	STRING64.	470	
If	two	or	more	genes	between	two	separate	BW	loci	were	connected,	they	were	given	an	increased	471	
prior	for	both	being	plausible	candidates.	We	also	applied	protein-protein	interaction	(PPI)	analysis	472	
(see	below	for	details)	to	all	genes	within	300	kb	of	each	lead	BW	SNPs	and	ranked	the	genes	based	473	
on	the	score	for	connectivity	with	the	surrounding	genes.			474	
	475	
Approximate	conditional	analysis.	We	searched	for	multiple	distinct	BW	association	signals	in	each	476	
of	the	established	and	novel	loci,	defined	as	1Mb	up-	and	down-stream	of	the	lead	SNP	from	the	477	
trans-ancestry	meta-analysis,	through	approximate	conditional	analysis.	We	applied	GCTA65	to	478	
identify	“index	SNPs”	for	distinct	association	signals	attaining	genome-wide	significance	(P<5x10-8)	in	479	
the	European	ancestry	meta-analysis	using	a	reference	sample	of	5,000	individuals	of	white	British	480	
origin,	randomly	selected	from	UK	Biobank,	to	approximate	patterns	of	linkage	disequilibrium	(LD)	481	
between	variants	in	these	regions.	Note	that	we	performed	approximate	conditioning	on	the	basis	of	482	
only	the	European	ancestry	meta-analysis	because	GCTA	cannot	accommodate	LD	variation	between	483	
diverse	populations.	484	
	485	
Fine-mapping	analyses.	We	sought	to	leverage	LD	differences	between	populations	contributing	to	486	
the	trans-ancestry	meta-analysis	and	to	take	advantage	of	the	improved	coverage	of	common	and	487	
low-frequency	variation	offered	by	1000G	or	1000G	and	UK10K	combined	imputation	to	localise	488	
variants	driving	each	distinct	association	signal	achieving	locus-wide	significance.	For	each	distinct	489	
signal,	we	used	MANTRA66	to	construct	99%	credible	sets	of	variants67	that	together	account	for	99%	490	
of	the	posterior	probability	of	driving	the	association.	MANTRA	incorporates	a	prior	model	of	491	
relatedness	between	studies,	based	on	mean	pair-wise	allele	frequency	differences	across	loci,	to	492	
account	for	heterogeneity	in	allelic	effects	(Supplementary	Table	3).	MANTRA	has	been	493	
demonstrated,	by	simulation,	to	improve	localisation	of	causal	variants	compared	with	either	a	494	
fixed-	or	random-effects	trans-ancestry	meta-analysis66,68.			495	
For	loci	with	only	one	signal	of	association,	we	used	MANTRA	to	combine	summary	statistics	496	
from	the	six	non-European	GWAS	and	the	two	European	ancestry	components.	However,	for	loci	497	
with	multiple	distinct	association	signals,	we	used	MANTRA	to	combine	summary	statistics	from	498	
approximate	conditioning	for	the	two	European	components,	separately	for	each	signal.	499	
For	each	distinct	signal,	we	calculated	the	posterior	probability	that	the	jth	variant,	πCj,	is	500	
driving	the	association,	given	by	501	
	502	 𝜋!! = !!!!! ,	503	
	504	
where	the	summation	is	over	all	variants	mapping	within	the	(conditional)	meta-analysis	across	the	505	
locus.	In	this	expression,	Λj	is	the	Bayes’	factor	(BF)	in	favour	of	association	from	the	MANTRA	506	
analysis.	A	99%	credible	set67	was	then	constructed	by:	(i)	ranking	all	variants	according	to	their	BF,	507	
Λj;	and	(ii)	including	ranked	variants	until	their	cumulative	posterior	probability	exceeds	0.99.	508	
	509	
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Genomic	annotation.	We	used	genomic	annotations	of	DNaseI	hypersensitive	sites	(DHS)	from	the	510	
ENCODE69	project	and	protein	coding	genes	from	GENCODE70.	We	filtered	cell	types	that	are	cancer	511	
cell	lines	(karyotype	‘cancer’	from	https://genome.ucsc.edu/ENCODE/cellTypes.html),	and	merged	512	
data	from	multiple	samples	from	the	same	cell	type.	This	resulted	in	128	DHS	cell-type	annotations,	513	
as	well	as	4	gene-based	annotations	(coding	exon,	5UTR,	3UTR	and	1kb	upstream	of	TSS).	First,	we	514	
tested	for	the	effect	of	each	cell	type	DHS	and	gene	annotation	individually	using	the	Bayes	Factors	515	
for	all	variants	in	the	62	credible	sets	using	fgwas71.	Second,	we	categorised	the	annotations	into	516	
‘genic’,	‘foetal	DHS’,	‘embryonic	DHS’,	‘stem	cell	DHS’,	‘neonatal	DHS’	and	‘adult	DHS’	based	on	the	517	
description	fields	from	ENCODE,	and	tested	for	the	effect	of	each	category	individually	as	described	518	
above	using	fgwas.	Third,	we	then	tested	the	effect	of	each	category	by	including	all	categories	in	a	519	
joint	model	using	fgwas.	For	each	of	the	three	analyses,	we	obtained	the	estimated	effects	and	95%	520	
confidence	intervals	(CI)	for	each	annotation,	and	considered	an	annotation	enriched	if	the	95%	CI	521	
did	not	overlap	zero.		522	
	523	
Evaluation	of	imputation	quality	of	low-frequency	variant	at	the	YKT6-GCK	locus.	At	the	YKT6-GCK	524	
locus,	the	lead	SNP	(rs138715366)	is	of	low-frequency	in	European	ancestry	populations	525	
(MAF=0.92%)	and	even	rarer	in	other	ancestry	groups	(MAF=0.23%	in	African	Americans,	otherwise	526	
monomorphic)	and	is	not	present	in	the	HapMap	reference	panel72.	To	assess	the	accuracy	of	527	
imputation	for	this	low-frequent	variant,	we	genotyped	rs138715366	in	the	Northern	Finland	Birth	528	
Cohort	(NFBC)	1966	(Supplementary	Table	1).	Of	the	5,009	samples	in	the	study,	4,704	were	529	
successfully	imputed	and	genotyped	(or	sequenced)	for	rs138715366.	The	overall	concordance	rate	530	
between	imputed	and	directly	assayed	genotypes	was	99.8%	and	for	directly	assayed	heterozygote	531	
calls	was	75.0%.		532	
	533	
Estimation	of	genetic	variance	explained.	Variance	explained	was	calculated	using	the	REML	534	
method	implemented	in	GCTA73.	We	considered	the	variance	explained	by	two	sets	of	SNPs:	(i)	lead	535	
SNPs	of	all	62	distinct	association	signals	at	the	59	established	and	novel	autosomal	BW	loci	536	
identified	in	the	European-specific	or	trans-ancestry	meta-analyses;	(ii)	lead	SNPs	of	55	distinct	537	
association	signals	at	the	52	novel	autosomal	BW	loci	(Extended	Data	2	and	Supplementary	Table	538	
7).	Variance	explained	was	calculated	in	samples	of	European	ancestry	in	the	Hyperglycemia	and	539	
Adverse	Pregnancy	Outcome	(HAPO)	study74	(independent	of	the	meta-analysis)	and	two	studies	540	
that	were	part	of	the	European	ancestry	meta-analysis:	NFBC1966	and	Generation	R	541	
(Supplementary	Table	1).	In	each	study,	the	genetic	relationship	matrix	was	estimated	for	each	set	542	
of	SNPs	and	was	tested	individually	against	BW	(males	and	females	combined)	with	study	specific	543	
covariates.	These	analyses	provided	an	estimate	and	standard	error	for	the	variance	explained	by	544	
each	of	the	given	sets	of	SNPs.	545	
	546	
Examining	the	relative	effects	on	BW	of	maternal	and	foetal	genotype	at	the	60	identified	loci.	We	547	
performed	four	sets	of	analyses:		548	
(i) We	used	GWAS	data	from	4,382	mother-child	pairs	in	the	Avon	Longitudinal	Study	of	549	
Parents	and	Children	(ALSPAC)	study	to	fit	a	“maternal-GCTA	model”6	to	estimate	the	550	
extent	to	which	the	maternal	genome	might	influence	offspring	BW	independent	of	the	551	
foetal	genome.	The	m-GCTA	model	uses	genome-wide	genetic	similarity	between	552	
mothers	and	offspring	to	partition	the	phenotypic	variance	in	BW	into	components	due	553	
to	the	maternal	genotype,	the	child’s	genotype,	the	covariance	between	the	two	and	554	
environmental	sources	of	variation;		555	
(ii) We	compared	associations	with	BW	of	the	foetal	versus	maternal	genotype	at	each	of	556	
the	60	BW	loci.	The	maternal	allelic	effect	on	offspring	BW	was	obtained	from	a	557	
maternal	GWAS	meta-analysis	of	68,254	European	mothers	from	the	EGG	Consortium	558	
(n=19,626)7	and	the	UK	Biobank	(n=48,628).	In	the	UK	Biobank,	mothers	were	asked	to	559	
report	the	BW	of	their	first	child.	Women	of	European	ancestry	with	genotype	data	560	
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available	in	the	May	2015	data	release	were	included,	and	those	with	reported	BW	561	
equivalent	to	<	2.5	kg	or	>	4.5kg	were	excluded.	No	information	on	gestational	age	or	562	
gender	of	child	was	available.	BW	of	first	child	was	associated	with	maternal	factors	such	563	
as	smoking	status,	BMI	and	height	in	the	expected	directions.	Of	the	68,254	women	564	
included	in	the	maternal	GWAS,	13%	were	mothers	of	individuals	included	in	the	current	565	
foetal	European	ancestry	GWAS,	and	a	further	approximately	45%	were	themselves	566	
(with	their	own	BW)	included	in	the	foetal	GWAS;		567	
(iii) We	additionally	conducted	analyses	in	12,909	mother-child	pairs	from	nine	contributing	568	
studies:	at	each	of	the	60	loci,	we	compared	the	effect	of	the	foetal	genotype	on	BW	569	
adjusted	for	sex	and	gestational	age,	with	and	without	adjustment	for	maternal	570	
genotype.	We	reciprocally	compared	the	association	between	the	maternal	genotype	571	
and	BW	with	and	without	adjustment	for	foetal	genotype;		572	
(iv) We	used	the	method	of	Zhang	et	al20	to	test	associations	between	BW	and	the	maternal	573	
untransmitted,	maternal	transmitted	and	paternal	transmitted	haplotype	score	of	422	574	
height	SNPs29,	30	SBP	SNPs18,19	and	84	T2D	SNPs28	in	5,201	mother-child	pairs	from	the	575	
ALSPAC	study.	576	
	577	
LD	Score	Regression.	The	use	of	LD	Score	regression	to	estimate	the	genetic	correlation	between	578	
two	traits/diseases	has	been	described	in	detail	elsewhere75.	Briefly,	“LD	Score”	is	a	measure	of	how	579	
much	genetic	variation	each	variant	tags;	if	a	variant	has	a	high	LD	Score	then	it	is	in	high	LD	with	580	
many	nearby	polymorphisms.	Variants	with	high	LD	Scores	are	more	likely	to	contain	more	true	581	
signals	and	hence	provide	more	chance	of	overlap	with	genuine	signals	between	GWAS.	The	LD	582	
score	regression	method	uses	summary	statistics	from	the	GWAS	meta-analysis	of	BW	and	the	other	583	
traits	of	interest,	calculates	the	cross-product	of	test	statistics	at	each	SNP,	and	then	regresses	the	584	
cross-product	on	the	LD	Score.	Bulik-Sullivan	et	al75	show	that	the	slope	of	the	regression	is	a	585	
function	of	the	genetic	covariance	between	traits:	586	
	587	
𝐸 𝑧!!𝑧!! = 𝑁!𝑁!𝜌!𝑀 𝑙! + 𝜌𝑁!𝑁!𝑁!	
where	Ni	is	the	sample	size	for	study	i,	ρg	is	the	genetic	covariance,	M	is	the	number	of	SNPs	in	the	588	
reference	panel	with	MAF	between	5%	and	50%,	lj	is	the	LD	score	for	SNP	j,	Ns	quantifies	the	number	589	
of	individuals	that	overlap	both	studies,	and	ρ	is	the	phenotypic	correlation	amongst	the	Ns	590	
overlapping	samples.	Thus,	if	there	is	sample	overlap	(or	cryptic	relatedness	between	samples),	it	591	
will	only	affect	the	intercept	from	the	regression	(i.e.	the	term	 !!!!!!!)	and	not	the	slope,	and	hence	592	
estimates	of	the	genetic	covariance	will	not	be	biased	by	sample	overlap.	Likewise,	population	593	
stratification	will	affect	the	intercept	but	will	have	minimal	impact	on	the	slope	(i.e.	intuitively	since	594	
population	stratification	does	not	correlate	with	linkage	disequilibrium	between	nearby	markers).	595	
Summary	statistics	from	the	GWAS	meta-analysis	for	traits	and	diseases	of	interest	were	596	
downloaded	from	the	relevant	consortium	website.	The	summary	statistics	files	were	reformatted	597	
for	LD	Score	regression	analysis	using	the	munge_sumstats.py	python	script	provided	on	the	598	
developer’s	website	(https://github.com/bulik/ldsc).	For	each	trait,	we	filtered	the	summary	599	
statistics	to	the	subset	of	HapMap	3	SNPs76,	as	advised	by	the	developers,	to	ensure	that	no	bias	was	600	
introduced	due	to	poor	imputation	quality.	Summary	statistics	from	the	European-specific	BW	meta-601	
analysis	were	used	because	of	the	variable	LD	structure	between	ancestry	groups.	Where	the	sample	602	
size	for	each	SNP	was	included	in	the	results	file	this	was	flagged	using	--N-col;	if	no	sample	size	was	603	
available	then	the	maximum	sample	size	reported	in	the	reference	for	the	GWAS	meta-analysis	was	604	
used.	SNPs	were	excluded	for	the	following	reasons:	MAF<0.01;	ambiguous	strand;	duplicate	rsID;	605	
non-autosomal	SNPs;	reported	sample	size	less	than	60%	of	the	total	available.	Once	all	files	were	606	
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reformatted,	we	used	the	ldsc.py	python	script,	also	on	the	developers’	website,	to	calculate	the	607	
genetic	correlation	between	BW	and	each	of	the	traits	and	diseases.	The	European	LD	Score	files	608	
that	were	calculated	from	the	1000G	reference	panel	and	provided	by	the	developers	were	used	for	609	
the	analysis.	Where	multiple	GWAS	meta-analyses	had	been	conducted	on	the	same	phenotype	(i.e.	610	
over	a	period	of	years),	the	genetic	correlation	with	BW	was	estimated	using	each	set	of	summary	611	
statistics	and	presented	in	Supplementary	Table	12.	The	phenotypes	with	multiple	GWAS	included	612	
height,	BMI,	waist-hip	ratio	(adjusted	for	BMI),	total	cholesterol,	triglycerides,	HDL	and	LDL.	The	613	
estimate	of	the	genetic	correlation	between	the	multiple	GWAS	meta-analyses	on	the	same	614	
phenotype	were	comparable	and	the	later	GWAS	had	a	smaller	standard	error	due	to	the	increased	615	
sample	size,	so	only	the	genetic	correlation	between	BW	and	the	most	recent	meta-analyses	were	616	
presented	in	Figure	2.	617	
In	the	published	GWAS	for	BP19	the	phenotype	was	adjusted	for	BMI.	Caution	is	needed	618	
when	interpreting	the	genetic	correlation	between	BW	and	BMI-adjusted	SBP	due	to	the	potential	619	
for	collider	bias77.	Since	BMI	is	associated	with	both	BP	and	BW,	it	is	possible	that	the	use	of	a	BP	620	
genetic	score	adjusted	for	BMI	might	bias	the	genetic	correlation	estimate	towards	a	more	negative	621	
value.	To	verify	that	the	inverse	genetic	correlation	with	BW	(rg=-0.26,	SE=0.05,	P=6.5x10-9)	was	not	622	
due	to	collider	bias	caused	by	the	BMI	adjustment	of	the	phenotype,	we	obtained	an	alternative	623	
estimate	using	UK	Biobank	GWAS	data	for	SBP	that	was	unadjusted	for	BMI	and	obtained	a	similar	624	
result	(rg=-0.22,	SE=0.03,	P=5.5x10-13).	The	SBP	phenotype	in	UK	Biobank	was	prepared	as	follows.	625	
Two	BP	readings	were	taken	at	assessment,	approximately	5	minutes	apart.	We	included	all	626	
individuals	with	an	automated	BP	reading	(taken	using	an	automated	Omron	BP	monitor).	Two	valid	627	
measurements	were	available	for	most	participants	(averaged	to	create	a	BP	variable,	or	628	
alternatively	a	single	reading	was	used	if	only	one	was	available).	Individuals	were	excluded	if	the	629	
two	readings	differed	by	more	than	4.56	SD.	BP	measurements	more	than	4.56	SD	away	from	the	630	
mean	were	excluded.	We	accounted	for	BP	medication	use	by	adding	15	mmHg	to	the	SBP	measure.	631	
BP	was	adjusted	for	age,	sex	and	centre	location	and	then	inverse	rank	normalised.	We	performed	632	
the	GWAS	on	127,698	individuals	of	British	descent	using	BOLT-LMM42,	with	genotyping	array	as	633	
covariate.	634	
	635	
Estimating	the	proportion	of	the	BW-adult	traits	covariance	attributable	to	genotyped	SNPs.	We	636	
estimated	the	phenotypic,	genetic	and	residual	correlations	as	well	as	the	genetic	and	residual	637	
covariance	between	BW	and	several	quantitative	traits/disease	outcomes	in	UK	Biobank	using	638	
directly	genotyped	SNPs	and	the	REML	method	implemented	in	BOLT-LMM42.	The	traits	examined	639	
included	T2D,	SBP,	DBP,	CAD,	height,	BMI,	weight,	waist-hip	ratio,	hip	circumference,	waist	640	
circumference,	obesity,	overweight,	age	at	menarche,	asthma,	and	smoking.	Where	phenotypes	641	
were	not	available	(e.g.	serum	blood	measures	are	not	currently	available	in	UK	Biobank),	we	642	
obtained	estimates	using	the	NFBC1966	study	(for	correlations/covariance	between	BW	and	643	
triglycerides,	Total-,	HDL-	and	LDL-cholesterol,	fasting	glucose	and	fasting	insulin).	In	the	UK	Biobank	644	
analysis,	we	used	57,715	unrelated	individuals	with	BW	available	and	identified	by	UK	Biobank	as	645	
white	British.	SNPs	with	evidence	of	deviation	from	Hardy-Weinberg	Equilibrium	(P<1x10-6),	646	
MAF<0.05	or	overall	missing	rate	>0.015	were	excluded,	resulting	in	328,928	SNPs	for	analysis.	We	647	
included	the	first	five	ancestry	principal	components	as	covariates.	In	the	NFBC1966	analysis,	5,009	648	
individuals	with	BW	were	enrolled.	Genotyped	SNPs	that	passed	quality	control	(Supplementary	649	
Table	2)	were	included,	resulting	in	324,895	SNPs	for	analysis.	The	first	three	ancestry	principal	650	
components	and	sex	were	included	as	covariates.	651	
	652	
Gene	set	enrichment	analysis.	Meta-Analysis	Gene-set	Enrichment	of	variaNT	Associations	653	
(MAGENTA)	was	used	to	explore	pathway-based	associations	using	summary	statistics	from	the	654	
trans-ancestry	meta-analysis.	MAGENTA	implements	a	gene	set	enrichment	analysis	(GSEA)	based	655	
approach,	as	previously	described13.	Briefly,	each	gene	in	the	genome	is	mapped	to	a	single	index	656	
SNP	with	the	lowest	P-value	within	a	110	kb	upstream	and	40	kb	downstream	window.	This	P-value,	657	
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representing	a	gene	score,	is	then	corrected	for	confounding	factors	such	as	gene	size,	SNP	density	658	
and	LD-related	properties	in	a	regression	model.	Genes	within	the	HLA-region	were	excluded	from	659	
analysis	due	to	difficulties	in	accounting	for	gene	density	and	LD	patterns.	Each	mapped	gene	in	the	660	
genome	is	then	ranked	by	its	adjusted	gene	score.	At	a	given	significance	threshold	(95th	and	75th	661	
percentiles	of	all	gene	scores),	the	observed	number	of	gene	scores	in	a	given	pathway,	with	a	662	
ranked	score	above	the	specified	threshold	percentile,	is	calculated.	This	observed	statistic	is	then	663	
compared	to	1,000,000	randomly	permuted	pathways	of	identical	size.	This	generates	an	empirical	664	
GSEA	P-value	for	each	pathway.	Significance	was	attained	when	an	individual	pathway	reached	a	665	
false	discovery	rate	(FDR)	<0.05	in	either	analysis.	In	total,	3,216	pre-defined	biological	pathways	666	
from	Gene	Ontology,	PANTHER,	KEGG	and	Ingenuity	were	tested	for	enrichment	of	multiple	modest	667	
associations	with	BW.	The	MAGENTA	software	was	also	used	for	enrichment	testing	of	custom	gene	668	
sets.	669	
	670	
Protein-Protein	interaction	network	analyses.	We	used	the	integrative	Protein-Interaction-671	
Network-Based	Pathway	Analysis	(iPINBPA)	method78.	Briefly,	we	generated	gene-wise	P-values	672	
from	the	trans-ancestry	meta-analysis	using	VEGAS279,	which	map	the	SNPs	to	genes	and	account	for	673	
possible	cofounders,	such	as	LD	between	markers.	The	empirical	gene-wise	P-values	are	calculated	674	
using	simulations	from	the	multivariate	normal	distribution.	Those	that	were	nominally	significant	675	
(P≤0.01)	were	selected	as	“seed	genes”,	and	were	collated	within	high	confidence	version	of	676	
inweb314,	to	weight	the	nodes	in	the	network	following	a	guilt-by-association	approach.	In	a	second	677	
step,	a	network	score	was	defined	by	the	combination	of	the	z-scores	derived	from	the	gene-wise	P-678	
values	with	node	weights	using	the	Liptak-Stouffer	method80.	A	heuristic	algorithm	was	then	applied	679	
to	extensively	search	for	modules	enriched	in	genes	with	low	P-values.	The	modules	were	further	680	
normalised	using	a	null	distribution	of	10,000	random	networks.	Only	those	modules	with	z-score	>5	681	
were	selected.	Finally,	the	union	of	all	modules	constructed	a	BW-overall	PPI	network.	Both	the	682	
proteins	on	the	individual	modules	and	on	the	overall	BW-PPI	were	interrogated	for	enrichment	in	683	
Gene	Ontology	Terms	(Biological	Processes)	using	a	Hypergeometric	test.	Terms	were	considered	as	684	
significant	when	adjusted	P-value,	following	Benjamini-Hochberg	procedure,	was	below	0.05.	685	
	686	
Point	of	contact	analyses	(PoC).	The	same	methodology	described	above	was	applied	to	16	different	687	
adult	traits	resulting	in	a	number	of	enriched	modules	per	trait.	Different	modules	for	each	trait	688	
were	combined	in	a	single	component	and	the	intersection	between	these	trait-specific	components	689	
and	the	BW	component	was	calculated.	This	intersection	is	defined	as	the	PoC	network.	We	used	the	690	
resulting	PoC	networks	in	downstream	analyses	to	interrogate	which	set	of	proteins	connects	BW	691	
variation	and	adult	trait	variation	via	pathways	enriched	in	the	overall	BW	analysis.	692	
	693	
Parent-of-origin	specific	associations.	We	first	searched	for	evidence	of	parent	of	origin	effects	in	694	
the	UK	Biobank	samples	by	comparing	variance	between	heterozygotes	and	homozygotes	using	695	
Quicktest81.	In	this	analysis,	we	used	only	unrelated	individuals	identified	genetically	as	of	white	696	
British	origin	(n=57,715).	Principal	components	were	generated	using	these	individuals	and	the	first	697	
five	were	used	to	adjust	for	population	structure	as	covariates	in	the	analysis,	in	addition	to	a	binary	698	
indicator	for	genotyping	array.	699	
We	also	examined	4,908	mother-child	pairs	in	ALSPAC	and	determined	the	parental	origin	of	700	
the	alleles	where	possible82.	Briefly,	the	method	uses	mother-child	pairs	to	determine	the	parent	of	701	
origin	of	each	allele.	For	example,	if	the	mother/child	genotypes	are	AA/Aa,	the	child’s	702	
maternal/paternal	allele	combination	is	A/a.	For	the	situation	where	both	mother	and	child	are	703	
heterozygous,	the	child’s	maternal/paternal	alleles	cannot	be	directly	specified.	However,	the	704	
parental	origin	of	the	alleles	can	be	determined	by	phasing	the	genotype	data	and	comparing	705	
maternal	and	child	haplotypes.	We	then	tested	these	alleles	for	association	with	BW	adjusting	for	706	
sex	and	gestational	age.		707	
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Statistical	power	in	these	currently	available	sample	sizes	is	insufficient	to	rule	out	708	
widespread	parent-of-origin	effects	across	the	regions	tested.	Using	the	mean	beta	(0.034SD)	and	709	
MAF	(0.28)	of	the	identified	loci,	we	estimate	that	we	would	need	at	least	200,000	unrelated	710	
individuals	or	70,000	mother-child	pairs	for	80%	power	to	detect	parent-of-origin	effects	at	711	
P<0.00085.	712	
	713	
Hierarchical	clustering	of	BW	loci.	To	explore	the	different	patterns	of	association	between	BW	and	714	
other	anthropometric/metabolic/endocrine	traits	and	diseases,	we	performed	hierarchical	clustering	715	
analysis.	The	lead	SNP	(or	proxy,	EUR	r2>0.6)	at	the	60	BW	loci	was	queried	in	publicly	available	716	
GWAS	meta-analysis	datasets	or	in	GWAS	result	obtained	through	collaboration83.	Results	were	717	
available	for	53	of	those	loci	and	the	extracted	z-score	(allelic	effect/SE,	Supplementary	Table	17)	718	
was	aligned	to	the	BW-raising	allele.	We	performed	2D	clustering	by	trait	and	by	locus.	We	719	
computed	the	Euclidean	distance	amongst	z-scores	of	the	extracted	traits/loci	and	performed	720	
complete	hierarchical	clustering	implemented	in	the	pvclust	package	(http://www.sigmath.es.osaka-721	
u.ac.jp/shimo-lab/prog/pvclust/)	in	R	v3.2.0	(http://www.R-project.org/).	Clustering	uncertainty	was	722	
measured	by	multiscale	bootstrap	resampling	estimated	from	1,000	replicates.	We	used	α=0.05	to	723	
define	distinct	clusters	and,	based	on	the	bootstrap	analysis,	calculated	the	Calinski	index	to	identify	724	
the	number	of	well-supported	clusters	(cascadeKM	function,	Vegan	package,	http://CRAN.R-725	
project.org/package=vegan).	Clustering	was	visualised	by	constructing	dendrograms	and	a	heatmap.	726	
	 Separately	from	the	hierarchical	clustering	analysis,	we	queried	the	lead	SNP	at	EPAS1	in	a	727	
GWAS	of	haematological	traits84	because	variation	at	that	locus	has	previously	been	implicated	in	728	
BW	and	adaptation	to	hypoxia	at	high	altitudes	in	Tibetans85,86	(Supplementary	Table	17).	729	
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FIGURE	LEGENDS	
	
Figure	1	|	Manhattan	and	quantile-quantile	(QQ)	plots	of	the	trans-ancestry	meta-analysis	for	
birth	weight.	a,	Manhattan	(main	panel)	and	QQ	(top	right)	plots	of	genome-wide	association	results	
for	birth	weight	from	trans-ancestry	meta-analysis	of	up	to	153,781	individuals.	The	association	P-
value	(on	-log10	scale)	for	each	of	up	to	22,185,636	SNPs	(y	axis)	is	plotted	against	the	genomic	
position	(NCBI	Build	37;	x	axis).	Association	signals	that	reached	genome-wide	significance	(P<5x10-8)	
are	shown	in	green	if	novel	and	pink	if	previously	reported.	In	the	QQ	plot,	the	black	dots	represent	
observed	P-values	and	the	grey	line	represents	expected	P-values	under	the	null	distribution.	The	
red	dots	represent	observed	P-values	after	excluding	the	previously	identified	signals	described	in	
Extended	Data	2.	b,	Manhattan	(main	panel)	and	QQ	(top	right)	plots	of	trans-ethnic	GWAS	meta-
analysis	for	BW	highlighting	the	reported	imprinted	regions	described	in	Supplementary	Table	14.	
Novel	association	signals	that	reached	genome-wide	significance	(P<5x10-8)	and	mapped	to	
imprinted	regions	are	shown	in	green.	Genomic	regions	outside	imprinted	regions	are	shaded	in	
grey.	SNPs	in	the	imprinted	regions	are	shown	in	light	blue	or	dark	blue,	if	they	are	on	chromosome	
with	odd	number	or	even	number,	respectively.	In	the	QQ	plot,	the	black	dots	represent	observed	P	
values	and	the	grey	lines	represent	expected	P-values	and	their	95%	confidence	intervals	under	the	
null	distribution	for	the	SNPs	within	the	imprinted	regions.		
	
Figure	2	|	Genome-wide	genetic	correlation	between	birth	weight	and	a	range	of	traits	and	
diseases	in	later	life.	Genetic	correlation	(rg)	and	corresponding	standard	error	between	birth	weight	
and	the	traits	displayed	on	the	x	axis	are	estimated	using	LD	Score	regression12.	The	genetic	
correlation	estimates	(rg)	are	colour	coded	according	to	their	intensity	and	direction	(red	for	positive	
and	blue	for	negative	correlation).	HC=head	circumference,	WHR=waist-hip	ratio,	WHR	(adj	
BMI)=waist-hip	ratio	adjusted	for	body	mass	index,	BMI=body	mass	index,	Pubertal	
growth=standardized	difference	in	height	between	age	8	and	adult	height,	Total	
growth=standardized	difference	in	height	at	age	14	and	adult	height,	CAD=coronary	artery	disease,	
DBP=diastolic	blood	pressure,	SBP=systolic	blood	pressure*,	Chol=total	cholesterol,	TG=triglycerides,	
LDL=low-density	lipoprotein,	HDL=high-density	lipoprotein,	T2D=type	2	diabetes,	HOMA-
B=homeostatic	model	assessment	of	beta-cell	function,	HOMA-IR=homeostatic	model	assessment	of	
insulin	resistance,	HbA1C=Hemoglobin	A1c,	LSBMD=lumbar	spine	bone	mineral	density,	
FNBMD=femoral	neck	bone	mineral	density,	Edu	Att=educational	attainment,	ADHD=attention	
deficit	hyperactivity	disorder,	Cigarettes/Day=number	of	cigarettes	per	day.	See	Supplementary	
Table	12	for	references	for	each	of	the	traits	and	diseases	displayed	here.		
	
Figure	3	|	Hierarchical	clustering	of	birth	weight	loci	based	on	similarity	of	overlap	with	adult	
diseases,	metabolic	and	anthropometric	traits.	For	the	lead	SNP	at	each	of	the	birth	weight	loci	
(listed	on	y	axis),	the	z-score	aligned	to	the	birth	weight-raising	allele	is	obtained	from	publicly	
available	GWAS	results	for	various	diseases	and	traits	(listed	on	x	axis)	and	are	displayed	in	the	
heatmap.	Of	the	60	birth	weight	loci,	z-score	for	lead	SNP	(or	proxy)	at	7	loci	were	not	available	(see	
Supplementary	Table	17).	Positive	z-scores	in	red	indicate	the	BW-raising	allele	increases	the	value	
of	the	trait	concerned,	and	negative	z-scores	in	blue	show	that	it	is	associated	with	decrease	of	the	
trait	value	of	interest.	Birth	weight	loci	and	traits	are	clustered	according	to	the	Euclidean	distance	
amongst	z-score	of	the	loci/traits	(see	Methods).	White	cross	with	a	black	circle	in	the	middle	
signifies	that	BW	locus	is	significantly	(P<5x10-8)	associated	with	the	trait	of	interest	in	the	publicly	
available	GWAS	look-up	(Supplementary	Table	17).	If	the	BW	locus	does	not	attain	P<5x10-8	in	the	
GWAS	look-up,	but	is	reported	significant	elsewhere,	it	is	marked	with	plain	white	cross.	For	
example,	ADRB1	(lead	BW	variant	rs7076938)	was	not	significantly	associated	with	various	
measurements	of	blood	pressure	in	Ehret	et	al.19	from	which	the	z-scores	were	extracted,	but	was	
reported	as	blood	pressure	locus	by	Johnson	et	al.18	and	Kato	et	al.87.	BMI=body	mass	index,	
CAD=coronary	artery	disease,	Chol=total	cholesterol,	DBP=diastolic	blood	pressure,	HC=head	
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circumference,	HDL=high-density	lipoprotein,	LDL=low-density	lipoprotein,	SBP=systolic	blood	
pressure,	TG=triglycerides,	T2D=type	2	diabetes,	WHRadjBMI=waist-hip	ratio	adjusted	for	BMI.		
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EXTENDED	DATA	LEGENDS	
	
Extended	Data	1	|	Flow	chart	of	the	study	design.	
	
Extended	Data	2	|	Sixty	loci	associated	with	birth	weight	(P<5x10-8)	in	European	ancestry	meta-
analysis	of	up	to	143,677	individuals	and/or	trans-ancestry	meta-analysis	of	up	to	153,781	
individuals.		
	
Extended	Data	3	|	Regional	plots	for	multiple	distinct	signals	at	three	birth	weight	loci,	ZBTB7B	(a),	
HMGA1	(b)	and	PTCH1	(c).	Regional	plots	for	each	locus	are	displayed	from:	the	unconditional	
European-specific	meta-analysis	of	up	to	143,677	individuals	(left);	the	approximate	conditional	
meta-analysis	for	the	primary	signal	after	adjustment	for	the	index	variant	for	the	secondary	signal	
(middle);	and	the	approximate	conditional	meta-analysis	for	the	secondary	signal	after	adjustment	
for	the	index	variant	for	the	primary	signal	(right).	Directly	genotyped	or	imputed	SNPs	are	plotted	
with	their	association	P-values	(on	a	-log10	scale)	as	a	function	of	genomic	position	(NCBI	Build	37).	
Estimated	recombination	rates	(blue	lines)	are	plotted	to	reflect	the	local	LD	structure	around	the	
index	SNPs	and	their	correlated	proxies.	SNPs	are	coloured	in	reference	to	LD	with	the	particular	
index	SNP	according	to	a	blue	to	red	scale	from	r2	=	0	to	1,	based	on	pairwise	r2	values	estimated	
from	a	reference	of	5,000	individuals	of	white	British	origin,	randomly	selected	from	the	UK	Biobank.				
	
Extended	Data	4	|	Absolute	effect	size	and	minor	allele	frequency	of	lead	SNPs	at	60	known	and	
novel	birth	weight	loci	from	the	trans-ancestry	meta-analysis	of	up	to	153,781	individuals.	The	
effect	of	the	lead	SNP	(absolute	value	of	beta,	y	axis)	is	given	as	a	function	of	minor	allele	frequency	
(x	axis)	for	known	birth	weight	loci	in	pink	and	novel	loci	in	green.	Error	bars	are	proportional	to	the	
standard	error	of	the	effect	size.	The	dashed	line	indicates	80%	power	to	detect	association	at	
genome-wide	significance	level	for	the	sample	size	in	trans-ancestry	meta-analysis.	All	birth	weight	
loci	were	common	except	for	two:	at	the	YKT6-GCK	locus,	the	index	SNP	(rs138715366)	was	of	low-
frequency	in	European	ancestry	populations	(MAF=0.92%),	and	even	rarer	in	other	ancestry	groups	
(MAF=0.23%	in	African	Americans,	otherwise	monomorphic).	Similarly,	at	the	SUZ12P1-CRLF3	locus,	
the	index	SNP	(rs144843919)	was	of	low-frequency	in	European	and	African	American	ancestry	
studies	(MAF	of	3.5%	and	4.0%,	respectively),	and	absent	from	other	ancestry	groups.	None	of	the	
variants	attaining	genome-wide	significance	in	European	ancestry	or	trans-ancestry	meta-analyses	at	
these	two	loci	was	present	in	HapMap,	suggesting	that	these	two	association	signals	would	not	have	
been	identified	without	imputation	up	to	the	denser	reference	panels	from	1000G/UK10K,	
irrespective	of	the	available	sample	size.	
	
Extended	Data	5	|	Comparison	of	foetal	effect	sizes	and	maternal	effect	sizes	at	60	known	and	
novel	birth	weight	loci	(continues	to	Extended	Data	6).	These	plots	illustrate	that	in	large	GWAS	of	
BW,	foetal	effect	size	estimates	are	larger	than	maternal	effect	size	estimates	at	55/60	identified	loci	
(binomial	P=1x10-11),	suggesting	that	most	of	the	associations	are	likely	to	be	driven	by	the	foetal	
genotype.	In	conditional	analyses	that	modelled	the	effects	of	both	maternal	and	foetal	genotypes	
(n=12,909	mother-child	pairs),	confidence	intervals	around	the	estimates	were	wide,	precluding	
inference	about	the	likely	contribution	of	maternal	vs.	foetal	genotype	at	individual	loci.	For	each	
birth	weight	locus,	the	following	six	effect	sizes	(with	95%	CI)	are	shown,	all	aligned	to	the	birth	
weight-raising	allele	in	the	overall	trans-ancestry	meta-analysis:	foetal_GWAS	=	foetal	allelic	effect	
on	birth	weight	(from	European	ancestry	meta-analysis	of	up	to	n=143,677	individuals);	
foetal_unadjusted	=	foetal	allelic	effect	on	birth	weight	(unconditioned	in	n=12,909	mother-child	
pairs);	foetal_adjusted	=	foetal	effect	conditioned	on	maternal	genotype	in	n=12,909	mother-child	
pairs);	maternal_GWAS	=	maternal	allelic	effect	on	offspring	birth	weight	(from	meta-analysis	of	up	
to	n=68,254	European	mothers)7;	maternal_unadjusted	=	maternal	allelic	effect	on	offspring	birth	
weight	(unconditioned	in	n=12,909	mother-child	pairs);	maternal_adjusted	=	maternal	effect	
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conditioned	on	foetal	genotype	(in	n=12,909	mother-child	pairs).	The	60	birth	weight	loci	are	
ordered	by	chromosome	and	position	(Supplementary	Tables	10	and	11).		
	
Extended	Data	6	|	Comparison	of	foetal	effect	sizes	and	maternal	effect	sizes	at	60	known	and	
novel	birth	weight	loci	(continued	from	Extended	Data	5).	The	scatterplot	illustrates	the	difference	
between	the	foetal	(x	axis)	and	maternal	(y	axis)	effect	sizes	in	the	overall	maternal	vs.	foetal	GWAS	
results.	
	
Extended	Data	7	|	Gene	set	enrichment	analysis	and	protein-protein	interaction	(PPI)	analysis.	
Two	complementary	analyses	of	the	overall	GWAS	summary	data	identified	enrichment	of	BW	
associations	in	biological	pathways	related	to	metabolism,	growth	and	development:	Table	(a)	shows	
the	top	results	(FDR<0.05	at	the	95th	percentile	enrichment	threshold)	from	a	total	of	3216	biological	
pathways	tested	for	enrichment	of	multiple	modest	associations	with	BW.	Additionally,	results	are	
presented	for	custom	sets	of	imprinted	genes.	In	Table	(b)	are	the	results	of	a	complementary	
analysis	of	empirical	PPI	data,	displaying	the	top	10	most	significant	pathways	enriched	for	BW-
association	scores.		
	
Extended	Data	8	|	Protein-Protein	Interaction	(PPI)	Network	analysis.	a,	illustrates	the	global	
largest	component	birth	weight	(BW)	PPI	network	containing	13	modules.	b,	the	histogram	shows	
the	null	distribution	of		z-scores	of	BW	PPI	networks	based	on	10,000	random	networks	and	where	
the	z-scores	for	the	13	birth	weight	modules	(M1-13)	lie.	For	each	module,	the	two	most	significant	
GO	terms	are	depicted.	c,	heatmap	showing	the	enrichment	for	the	top	50	biological	processes	over-
represented	in	the	global	BW	PPI	network	of	the	trait-specific	“point	of	contact“	(PoC)	PPI	networks.		
d-e,	trait-specific	PoC	PPI	networks	composed	of	proteins	that	are	shared	in	both	the	global	birth	
weight	PPI	network	and	networks	generated	using	the	same	pipeline	for	each	of	the	adult	traits:	d,	
canonical	Wnt	signalling	pathway	enriched	for	PoC	PPI	between	BW	and	blood	pressure	(BP)-related	
phenotypes;	and	e,	regulation	of	insulin	secretion	pathway	enriched	for	PoC	between	BW	and	type	2	
diabetes	(T2D)/fasting	glucose	(FG).	Red	nodes	are	those	that	are	present	in	PoC	for	BW	and	traits	of	
interest;	blue	nodes	correspond	to	the	pathway	nodes;	purple	nodes	are	those	present	in	both	the	
pathway	and	PoC.	Large	nodes	correspond	to	genes	in	BW	loci	(within	300kb	from	the	lead	SNP),	and	
are	orange	when	they	overlap	the	enriched	pathway	and	the	PoC,	and	have	black	border	if	they,	
amongst	all	BW	loci,	have	a	stronger	(top	5)	association	with	at	least	one	of	the	pairing	adult	traits.	
	
Extended	Data	9	|	Quantile-Quantile	(QQ)	plots	of	(a)	variance	comparison	between	
heterozygotes	and	homozygotes	analysis	in	57,715	UK	Biobank	samples	and	(b)	parent-of-origin	
specific	analysis	in	4,908	ALSPAC	mother-child	pairs	at	59	autosomal	birth	weight	loci	plus	DLK1.	
Despite	the	large	sample	size,	especially	of	unrelated	individuals,	these	analyses	were	underpowered	
to	detect	parent-of-origin-specific	effects	at	the	identified	loci.	a,	QQ	plot	from	the	Quicktest81	
analysis	comparing	the	BW	variance	of	heterozygotes	with	homozygotes	in	57,715	UK	Biobank	
samples.	b,	QQ	plot	from	the	parent-of-origin	specific	analysis	testing	the	association	between	birth	
weight	and	maternally	transmitted	vs.	paternally	transmitted	alleles	in	4,908	mother-child	pairs	from	
the	ALSPAC	study	(Methods,	Supplementary	Tables	15	and	16).	In	both	panels,	the	black	dots	
represent	lead	SNPs	at	59	identified	autosomal	birth	weight	loci	and	a	further	sub-genome-wide	
significant	signal	for	birth	weight	near	DLK1	(rs6575803;	P=5.6x10-8).	The	grey	lines	represent	
expected	P	values	and	their	95%	confidence	intervals	under	the	null	distribution	for	the	60	SNPs.		
	
Extended	Data	10	|	Summary	of	previously	reported	loci	for	systolic	blood	pressure	(SBP,	a),	
coronary	artery	disease	(CAD,	b,	e),	type	2	diabetes	(T2D,	c,	f)	and	adult	height	(d)	and	their	effect	
on	birth	weight.	a-d,	Effect	sizes	(left	y	axis)	of	previously	reported	30	SBP	loci18,19,	45	CAD	loci27,	84	
T2D	loci28	and	422	adult	height	loci29	are	plotted	against	changes	in	birth	weight	z-score	(x	axis).	
Effect	sizes	are	aligned	to	the	adult	trait-raising	allele.	The	colour	of	each	dot	indicates	birth	weight	
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association	P	value:	red,	P<5×10−8;	orange,	5×10−8≤P<0.001;	yellow,	0.001≤P<0.01;	white,	P≥0.01.	
The	superimposed	grey	frequency	histogram	shows	the	number	of	SNPs	(right	y	axis)	in	each	
category	of	birth	weight	effect	size.	e,	Effect	sizes	(with	95%	CI)	on	BW	of	45	known	CAD	loci	are	
plotted	arranged	in	the	order	of	CAD	effect	size	from	highest	to	lowest,	separating	out	the	known	
SBP	loci	and	f,	those	of	32	known	T2D	loci	are	plotted,	subdivided	by	previously	reported	categories	
derived	from	detailed	adult	physiological	data31.	Heterogeneity	in	BW	effect	sizes	between	five	T2D	
loci	groups	with	different	mechanistic	categories	was	substantial	(Phet=1.2x10-9).	In	pairwise	
comparisons,	the	“beta	cell”	group	of	variants	differed	from	the	other	four	groups:	fasting	
hyperglycaemia	(Phet	=3x10-11),	insulin	resistance	(Phet	=0.002),	proinsulin	(Phet	=0.78)	and	unclassified	
(Phet	=0.02)	groups.	All	of	the	birth	weight	effect	sizes	plotted	in	the	forest	plots	are	aligned	to	the	
trait	(or	risk)-raising	allele.	



